Albumin prevents kidney injury but is underutilized in a cohort of patients undergoing large-volume paracentesis
- PMID: 41021268
- PMCID: PMC12483065
- DOI: 10.1097/HC9.0000000000000760
Albumin prevents kidney injury but is underutilized in a cohort of patients undergoing large-volume paracentesis
Abstract
Background: Cirrhosis and cirrhosis-related deaths have risen in the United States in recent years. Ascites is a common complication, often requiring large-volume paracentesis (LVP). The American Association for the Study of Liver Diseases (AASLD) recommends the administration of albumin in conjunction with LVP to prevent further complications of cirrhosis. Emerging research in cirrhosis care reveals significant variations in outcomes among different demographics. Therefore, we assessed the use of guideline-adherent albumin and outcomes in U.S. patients undergoing LVPs, particularly at the intersection of race, ethnicity, socioeconomic disparities, and cirrhosis.
Methods: This retrospective study utilized Cerner Real World Data to identify adults with cirrhosis and ascites undergoing LVP between January 2016 and June 2022. We assessed albumin utilization patterns across racial and ethnic groups and payor types, and their overall impact on acute kidney injury (AKI)-related hospitalization using an adjusted generalized linear model (aGLM).
Results: We identified 736 patients: 301 in the LVP + albumin group and 435 in the LVP-only group. Despite clinical recommendations, only 41% undergoing LVPs received albumin. White patients and commercially insured patients received albumin at higher rates (p=0.042 and p=0.009, respectively). The overall rate of AKI-related admissions within the 30-day post-procedure period was 26%. However, patients who received albumin during LVP had a 36% lower risk of short-term AKI-related hospitalization (OR: 0.64; p=0.03).
Conclusions: These findings indicate a potential for broader albumin utilization in U.S. patients with refractory ascites undergoing repeated LVPs to reduce AKI-related admissions.
Keywords: decompensated cirrhosis; pharmacoequity; real-world evidence; social determinants of health; structural racism.
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Conflict of interest statement
Elisabet Viayna and Cristina Coll-Ortega are employees of Grifols. Thomas Ardiles is an employee of Grifols, SSNA. W. Ray Kim serves as an advisor to Grifols SSNA and has contributed to research supported by Grifols SSNA. He received no personal financial remuneration for this study. At the time of the study, E. Anne Davis was an employee of Grifols, S.A. Rahul Rajkumar, Jonathan Lilley, Xuan Zhang, Nisha Wadhwani and Kunal Lodaya are employees of Boston Strategic Partners. Nikki Duong has no conflicts of interest to disclose.
Figures



References
-
- Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, et al. The epidemiology of cirrhosis in the United States: A population-based study. J Clin Gastroenterol. 2015;49:690–696. - PubMed
-
- Talwalkar JA. Prophylaxis with beta blockers as a performance measure of quality health care in cirrhosis. Gastroenterology. 2006;130:1005–1007. - PubMed
-
- Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330:337–342. - PubMed
-
- Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74:1014–1048. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical